Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H23FINO2 |
| Molecular Weight | 430.2861 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C(I)C=C3)N2CCC[18F]
InChI
InChIKey=HXWLAJVUJSVENX-LNYNZGDVSA-N
InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i19-1
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9352532 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Unknown Approved UseUnknown |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
175.9 h |
167 MBq single, intravenous dose: 167 MBq route of administration: Intravenous experiment type: SINGLE co-administered: |
IOFLUPANE I-123 blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.5% |
IOFLUPANE I-123 blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Head-to-head comparison of 18 F-FP-CIT and 123 I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study. | 2018-07 |
|
| [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. | 1997-10 |
|
| Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. | 1996-11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00468078
18F-beta-CIT-FP is administered instravenously at 5mCi 90 min before PET procedure
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
451114
Created by
admin on Tue Apr 01 16:34:55 GMT 2025 , Edited by admin on Tue Apr 01 16:34:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NT4P0L3OCX
Created by
admin on Tue Apr 01 16:34:55 GMT 2025 , Edited by admin on Tue Apr 01 16:34:55 GMT 2025
|
PRIMARY | |||
|
186381-69-1
Created by
admin on Tue Apr 01 16:34:55 GMT 2025 , Edited by admin on Tue Apr 01 16:34:55 GMT 2025
|
PRIMARY | |||
|
11626128
Created by
admin on Tue Apr 01 16:34:55 GMT 2025 , Edited by admin on Tue Apr 01 16:34:55 GMT 2025
|
PRIMARY |
ACTIVE MOIETY